ADRO Earns Milestone Payment, Hope & Allstar Await CAPR, CATB Ahead Of Time

Catabasis Pharmaceuticals Inc. (CATB) now expects to report top-line results from its phase 2a trial of CAT-2054 in hypercholesterolemia around mid-year 2016 compared to its earlier estimate of Q3, 2016.

from RTT - Biotech http://ift.tt/1YpjPxl
via IFTTT